PubRank

Gabriele Schaefer

Author PubWeight™ 14.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013 2.06
2 Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 2013 1.89
3 Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov 2012 1.86
4 The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J Mol Biol 2008 1.41
5 Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol 2012 1.12
6 Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med 2013 1.01
7 Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine. J Mol Biol 2010 0.91
8 LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J Biol Chem 2012 0.88
9 Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2011 0.87
10 Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PLoS One 2012 0.84
11 Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation. J Med Chem 2014 0.82
12 Engineering upper hinge improves stability and effector function of a human IgG1. J Biol Chem 2011 0.80
13 Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. J Med Chem 2015 0.76
14 Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. J Med Chem 2016 0.75
15 Correction to Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. J Med Chem 2016 0.75